1 / 1

Mavacamten(Camzyos)

Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection

Reference price:

Manufacturer:

Formulation:

CAPSULE

Validity period:

Not specified in the specification.

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

CAMZYOS (mavacamten) is an oral, allosteric, and reversible cardiac myosin inhibitor designed to modulate the number of myosin heads entering power-generating states, thereby reducing excessive contractility characteristic of hypertrophic cardiomyopathy. By selectively targeting cardiac myosin, CAMZYOS decreases left ventricular outflow tract (LVOT) obstruction and improves cardiac filling pressures, addressing the underlying pathophysiology of obstructive HCM.

The pharmacological action of CAMZYOS results in a dose-dependent reduction in LVOT gradients and improvement in exercise capacity and symptoms, as demonstrated in clinical trials. Due to its potential to cause systolic dysfunction and heart failure, careful patient selection, regular echocardiographic monitoring, and adherence to the CAMZYOS REMS Program are mandatory to ensure safe administration. The safety and efficacy in populations outside the specified indication, including pediatric and pregnant patients, are not specified in the specification.

Generic name

Mavacamten(Camzyos)

English name

Mavacamten

Alternative Names

Camzyos

Drug prices

Indications

CAMZYOS is indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.

Therapeutic Target

Cardiac myosin; specifically, CAMZYOS is a selective, allosteric, and reversible inhibitor of cardiac myosin, modulating the number of myosin heads entering power-generating states to reduce left ventricular outflow tract (LVOT) obstruction.

Active Ingredients

Mavacamten

Dosage form

CAPSULE

specifications

Capsules are imprinted with the strength and “Mava” and are available as: 2.5 mg (light purple cap) 5 mg (yellow cap) 10 mg (pink cap) 15 mg (gray cap)

Description

CAMZYOS capsules contain mavacamten, a cardiac myosin inhibitor. Mavacamten is a white to off-white powder, practically insoluble in water, with a molecular formula of C₁₅H₁₉N₃O₂ and a molecular weight of 273.33 g/mol. Inactive ingredients include croscarmellose sodium, hypromellose, magnesium stearate, mannitol, and silicon dioxide. The capsule shell contains black edible ink, black iron oxide, gelatin, red iron oxide, titanium dioxide, and yellow iron oxide.

Dosage and Administration

The recommended starting dose is 5 mg orally once daily, with or without food.

Allowable titration doses are 2.5 mg, 5 mg, 10 mg, or 15 mg once daily.

Maximum recommended dose is 15 mg once daily.

Dosing is individualized based on clinical status and echocardiographic assessment (LVEF and Valsalva LVOT gradient).

Initiation is not recommended in patients with LVEF <55%. Interrupt treatment if LVEF <50% or if clinical status worsens.

Capsules must be swallowed whole; do not break, open, or chew.

Missed doses should be taken as soon as possible, but two doses should not be taken on the same day.

CATEGORY NAVIGATION